| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/01/2001 | CA2379834A1 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | CA2379815A1 Parenteral cisplatin emulsion |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379777A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | CA2379251A1 Highly purified cytokine activating factor and methods of use |
| 02/01/2001 | CA2378860A1 Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| 02/01/2001 | CA2378849A1 Apicidin-derived cyclic tetrapeptides |
| 02/01/2001 | CA2378726A1 Compositions containing muscle-derived active agents |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378371A1 Use of etodolac to treat cancer |
| 02/01/2001 | CA2376465A1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | CA2375571A1 Human nervous system-associated proteins |
| 01/31/2001 | EP1072687A2 Method for testing metastatic potential and method for screening compounds with metastasis-suppressing activity |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1072607A2 Purine L-nucleosides, analogs and uses therof |
| 01/31/2001 | EP1072597A1 Pyrazoles and their use as endothelin antagonists |
| 01/31/2001 | EP1072272A1 Method for producing a specific antiserum against the universal tumorous antigen and method for diagnosing malignant tumours using said antiserum |
| 01/31/2001 | EP1071957A1 Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof |
| 01/31/2001 | EP1071805A2 Adenoviral vectors for treating disease |
| 01/31/2001 | EP1071794A1 A method for inhibiting tumor invasion or spreading in a subject |
| 01/31/2001 | EP1071787A1 Tao protein kinases and methods of use |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071777A2 Human nucleic acid sequences of normal uterus tissue |
| 01/31/2001 | EP1071776A2 Human nucleic acid sequences of normal bladder tissue |
| 01/31/2001 | EP1071764A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN $g(a) v?-SUBUNIT EXPRESSION |
| 01/31/2001 | EP1071753A2 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 01/31/2001 | EP1071752A1 CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| 01/31/2001 | EP1071749A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 01/31/2001 | EP1071745A2 Process for synthesizing cox-2 inhibitors |
| 01/31/2001 | EP1071717A1 Mutagenized il13-based chimeric molecules |
| 01/31/2001 | EP1071708A1 Edg family gene, human h218 |
| 01/31/2001 | EP1071704A1 Novel matrix metalloproteinase inhibitors and down-regulators |
| 01/31/2001 | EP1071700A1 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/31/2001 | EP1071696A1 Programmed cell death and caspase-12 |
| 01/31/2001 | EP1071684A1 IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS |
| 01/31/2001 | EP1071680A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/31/2001 | EP1071668A1 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 01/31/2001 | EP1071665A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes |
| 01/31/2001 | EP1071658A2 Btk inhibitors and methods for their identification and use |
| 01/31/2001 | EP1071470A1 COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN DELIVERY TO ANTIGEN PRESENTING CELLS $i(IN VIVO) |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071460A1 INTERNALIZING ErbB2 ANTIBODIES |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071450A2 Combination of antigen pulsed apcs and interleukin 12 for tumour and viral therapy |
| 01/31/2001 | EP1071443A1 Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein bind to mhc class i and mhc class ii molecules, and uses thereof |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071428A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/31/2001 | EP1071423A1 Antagonists of gonadotropin releasing hormone |
| 01/31/2001 | EP1071420A1 Indolyl-3-glyoxylic acid derivatives with antitumoral activity |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071333A1 Induction of immunity against tumor self-antigens |
| 01/31/2001 | EP1071329A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 01/31/2001 | EP1071327A1 Autoantigenic fragments, methods and assays |
| 01/31/2001 | CN1282372A Mammalian sytokine-like polypeptide-10 |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282336A Hemiasterlin analogs |
| 01/31/2001 | CN1282332A Novel acronycine compounds, preparation method and pharmaceutical compositions containing them |
| 01/31/2001 | CN1282255A IFNAR2/I FN complex |
| 01/31/2001 | CN1282245A Molecular dispersion composition with enhanced bioavailability |
| 01/31/2001 | CN1282242A Multicatalytic protease inhibitors for use as anti-tumor agents |
| 01/31/2001 | CN1282218A Compositions and method for treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 01/31/2001 | CN1281862A Three-chain formed oligonucleotide capable of inhibiting platelet derived growth factor gene expression and its application |
| 01/31/2001 | CN1281721A Chinese medicine cancer-digesting preparation and its production method |
| 01/31/2001 | CN1281706A Chinese medicine composition for curing various cancers |
| 01/31/2001 | CN1281699A Preparation of EIA-specicial medicinal compound for making medicine for resisting heat-cervical tumor and its application |
| 01/31/2001 | CN1061255C Anti-radioactivity fibration drug |
| 01/30/2001 | US6180773 The cc type chemokines belong to a family of polypeptides which have proven to be mediators of immune reactions, and which have antiviral activity with respect to hiv |
| 01/30/2001 | US6180766 Nucleosides and oligonucleotides containing boron clusters |
| 01/30/2001 | US6180676 Guanylhydrazones and their use to treat inflammatory conditions |
| 01/30/2001 | US6180650 Antiinflammatory agents; respiratory system disorders; skin disorders; antitumor agents |
| 01/30/2001 | US6180644 Immunotherapeutic agents |
| 01/30/2001 | US6180643 Antagonist of interleukins, tumor necrosis factor |
| 01/30/2001 | US6180636 Substituted pyrrolopyrimidines and processes for their preparation |
| 01/30/2001 | US6180632 Use of these compounds for treating disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or t cell activation and proliferation |
| 01/30/2001 | US6180631 Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
| 01/30/2001 | US6180619 Prenyl transferase inhibitors |
| 01/30/2001 | US6180613 AAV-mediated delivery of DNA to cells of the nervous system |
| 01/30/2001 | US6180611 Inhibitors of matrix metalloproteinases and tumor necrosis factor |
| 01/30/2001 | US6180608 Packaged formulation for treating a subject for a condition treatable with an lhrh analogue, comprising ionic complex of lhrh analogue and carrier macromolecule |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180384 Compounds |
| 01/30/2001 | US6180380 Cloning of a new member of the serine threonine kinase family |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | US6180362 Peptides which inhibit ras protein activity, their preparation and use |
| 01/30/2001 | US6180353 Nucleotide sequences associated with suppression of transcription binding protein associated with apoptosis; for the treatment and prevention defects associated with apoptosis |
| 01/30/2001 | US6180097 For treatment of solid tumors, including their metastases, without radiation, surgery or standard chemotherapeutic by using superantigens, including staphyloccocal enterotoxins b and c, to stimulate tumor draining lymph node cells |
| 01/30/2001 | US6180087 Tunable indocyanine dyes for biomedical applications |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/30/2001 | CA2272317C Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 01/30/2001 | CA2056997C A human cytokine, interleukin-9 |
| 01/30/2001 | CA2053268C Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| 01/30/2001 | CA2011171C Biodegradable poly (phosphate esters) |
| 01/29/2001 | CA2314682A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/28/2001 | CA2314572A1 Estrogen agonists and antagonists for multiple indications |
| 01/25/2001 | WO2001006756A2 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 01/25/2001 | WO2001006010A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 01/25/2001 | WO2001006005A2 Diagnostic method comprising wt1 sequences |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |